Cancer and All-cause Mortality in Bladder Cancer Patients Undergoing Radical Cystectomy: Development and Validation of a Nomogram for Treatment Decision-making

Stephen Williams, Jinhai Huo, Yiyi Chu, Jacques Baillargeon, Timothy Daskivich, Yong Fang Kuo, Christopher D. Kosarek, Simon P. Kim, Eduardo Orihuela, Douglas Tyler, Stephen J. Freedland, Ashish M. Kamat

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: To develop and validate a nomogram assessing cancer and all-cause mortality following radical cystectomy. Given concerns regarding the morbidity associated with surgery, there is a need for incorporation of cancer-specific and competing risks into patient counseling and recommendations. Materials and Methods: A total of 5325 and 1257 diagnosed with clinical stage T2-T4a muscle-invasive bladder cancer from January 1, 2006 to December 31, 2011 from Surveillance, Epidemiology, and End Results-Medicare and Texas Cancer Registry-Medicare linked data, respectively. Cox proportional hazards models were used and a nomogram was developed to predict 3- and 5-year overall and cancer-specific survival with external validation. Results: Patients who underwent radical cystectomy were mostly younger, male, married, non-Hispanic white and had fewer comorbidities than those who did not undergo radical cystectomy (P < .001). Married patients, in comparison with their unmarried counterparts, had both improved overall (hazard ratio 0.76; 95% confidence interval 0.70-0.83, P < .001) and cancer-specific (hazard ratio 0.76; 95% confidence interval 0.68-0.85, P < .001) survival. A nomogram developed using Surveillance, Epidemiology, and End Results-Medicare data, predicted 3- and 5-year overall and cancer-specific survival rates with concordance indices of 0.65 and 0.66 in the validated Texas Cancer Registry-Medicare cohort, respectively. Conclusion: Older, unmarried patients with increased comorbidities are less likely to undergo radical cystectomy. We developed and validated a generalizable instrument that has been converted into an online tool (Radical Cystectomy Survival Calculator), to provide a benefit-risk assessment for patients considering radical cystectomy.

Original languageEnglish (US)
JournalUrology
DOIs
StateAccepted/In press - 2017

Fingerprint

Nomograms
Cystectomy
Urinary Bladder Neoplasms
Decision Making
Medicare
Mortality
Neoplasms
Therapeutics
Survival
Registries
Comorbidity
Epidemiology
Confidence Intervals
Proportional Hazards Models
Counseling
Survival Rate
Morbidity
Muscles

ASJC Scopus subject areas

  • Urology

Cite this

Cancer and All-cause Mortality in Bladder Cancer Patients Undergoing Radical Cystectomy : Development and Validation of a Nomogram for Treatment Decision-making. / Williams, Stephen; Huo, Jinhai; Chu, Yiyi; Baillargeon, Jacques; Daskivich, Timothy; Kuo, Yong Fang; Kosarek, Christopher D.; Kim, Simon P.; Orihuela, Eduardo; Tyler, Douglas; Freedland, Stephen J.; Kamat, Ashish M.

In: Urology, 2017.

Research output: Contribution to journalArticle

Williams, Stephen ; Huo, Jinhai ; Chu, Yiyi ; Baillargeon, Jacques ; Daskivich, Timothy ; Kuo, Yong Fang ; Kosarek, Christopher D. ; Kim, Simon P. ; Orihuela, Eduardo ; Tyler, Douglas ; Freedland, Stephen J. ; Kamat, Ashish M. / Cancer and All-cause Mortality in Bladder Cancer Patients Undergoing Radical Cystectomy : Development and Validation of a Nomogram for Treatment Decision-making. In: Urology. 2017.
@article{4a26a0594afa4e318de30e1ac69409a9,
title = "Cancer and All-cause Mortality in Bladder Cancer Patients Undergoing Radical Cystectomy: Development and Validation of a Nomogram for Treatment Decision-making",
abstract = "Objective: To develop and validate a nomogram assessing cancer and all-cause mortality following radical cystectomy. Given concerns regarding the morbidity associated with surgery, there is a need for incorporation of cancer-specific and competing risks into patient counseling and recommendations. Materials and Methods: A total of 5325 and 1257 diagnosed with clinical stage T2-T4a muscle-invasive bladder cancer from January 1, 2006 to December 31, 2011 from Surveillance, Epidemiology, and End Results-Medicare and Texas Cancer Registry-Medicare linked data, respectively. Cox proportional hazards models were used and a nomogram was developed to predict 3- and 5-year overall and cancer-specific survival with external validation. Results: Patients who underwent radical cystectomy were mostly younger, male, married, non-Hispanic white and had fewer comorbidities than those who did not undergo radical cystectomy (P < .001). Married patients, in comparison with their unmarried counterparts, had both improved overall (hazard ratio 0.76; 95{\%} confidence interval 0.70-0.83, P < .001) and cancer-specific (hazard ratio 0.76; 95{\%} confidence interval 0.68-0.85, P < .001) survival. A nomogram developed using Surveillance, Epidemiology, and End Results-Medicare data, predicted 3- and 5-year overall and cancer-specific survival rates with concordance indices of 0.65 and 0.66 in the validated Texas Cancer Registry-Medicare cohort, respectively. Conclusion: Older, unmarried patients with increased comorbidities are less likely to undergo radical cystectomy. We developed and validated a generalizable instrument that has been converted into an online tool (Radical Cystectomy Survival Calculator), to provide a benefit-risk assessment for patients considering radical cystectomy.",
author = "Stephen Williams and Jinhai Huo and Yiyi Chu and Jacques Baillargeon and Timothy Daskivich and Kuo, {Yong Fang} and Kosarek, {Christopher D.} and Kim, {Simon P.} and Eduardo Orihuela and Douglas Tyler and Freedland, {Stephen J.} and Kamat, {Ashish M.}",
year = "2017",
doi = "10.1016/j.urology.2017.08.024",
language = "English (US)",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Cancer and All-cause Mortality in Bladder Cancer Patients Undergoing Radical Cystectomy

T2 - Development and Validation of a Nomogram for Treatment Decision-making

AU - Williams, Stephen

AU - Huo, Jinhai

AU - Chu, Yiyi

AU - Baillargeon, Jacques

AU - Daskivich, Timothy

AU - Kuo, Yong Fang

AU - Kosarek, Christopher D.

AU - Kim, Simon P.

AU - Orihuela, Eduardo

AU - Tyler, Douglas

AU - Freedland, Stephen J.

AU - Kamat, Ashish M.

PY - 2017

Y1 - 2017

N2 - Objective: To develop and validate a nomogram assessing cancer and all-cause mortality following radical cystectomy. Given concerns regarding the morbidity associated with surgery, there is a need for incorporation of cancer-specific and competing risks into patient counseling and recommendations. Materials and Methods: A total of 5325 and 1257 diagnosed with clinical stage T2-T4a muscle-invasive bladder cancer from January 1, 2006 to December 31, 2011 from Surveillance, Epidemiology, and End Results-Medicare and Texas Cancer Registry-Medicare linked data, respectively. Cox proportional hazards models were used and a nomogram was developed to predict 3- and 5-year overall and cancer-specific survival with external validation. Results: Patients who underwent radical cystectomy were mostly younger, male, married, non-Hispanic white and had fewer comorbidities than those who did not undergo radical cystectomy (P < .001). Married patients, in comparison with their unmarried counterparts, had both improved overall (hazard ratio 0.76; 95% confidence interval 0.70-0.83, P < .001) and cancer-specific (hazard ratio 0.76; 95% confidence interval 0.68-0.85, P < .001) survival. A nomogram developed using Surveillance, Epidemiology, and End Results-Medicare data, predicted 3- and 5-year overall and cancer-specific survival rates with concordance indices of 0.65 and 0.66 in the validated Texas Cancer Registry-Medicare cohort, respectively. Conclusion: Older, unmarried patients with increased comorbidities are less likely to undergo radical cystectomy. We developed and validated a generalizable instrument that has been converted into an online tool (Radical Cystectomy Survival Calculator), to provide a benefit-risk assessment for patients considering radical cystectomy.

AB - Objective: To develop and validate a nomogram assessing cancer and all-cause mortality following radical cystectomy. Given concerns regarding the morbidity associated with surgery, there is a need for incorporation of cancer-specific and competing risks into patient counseling and recommendations. Materials and Methods: A total of 5325 and 1257 diagnosed with clinical stage T2-T4a muscle-invasive bladder cancer from January 1, 2006 to December 31, 2011 from Surveillance, Epidemiology, and End Results-Medicare and Texas Cancer Registry-Medicare linked data, respectively. Cox proportional hazards models were used and a nomogram was developed to predict 3- and 5-year overall and cancer-specific survival with external validation. Results: Patients who underwent radical cystectomy were mostly younger, male, married, non-Hispanic white and had fewer comorbidities than those who did not undergo radical cystectomy (P < .001). Married patients, in comparison with their unmarried counterparts, had both improved overall (hazard ratio 0.76; 95% confidence interval 0.70-0.83, P < .001) and cancer-specific (hazard ratio 0.76; 95% confidence interval 0.68-0.85, P < .001) survival. A nomogram developed using Surveillance, Epidemiology, and End Results-Medicare data, predicted 3- and 5-year overall and cancer-specific survival rates with concordance indices of 0.65 and 0.66 in the validated Texas Cancer Registry-Medicare cohort, respectively. Conclusion: Older, unmarried patients with increased comorbidities are less likely to undergo radical cystectomy. We developed and validated a generalizable instrument that has been converted into an online tool (Radical Cystectomy Survival Calculator), to provide a benefit-risk assessment for patients considering radical cystectomy.

UR - http://www.scopus.com/inward/record.url?scp=85030464709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030464709&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2017.08.024

DO - 10.1016/j.urology.2017.08.024

M3 - Article

C2 - 28847688

AN - SCOPUS:85030464709

JO - Urology

JF - Urology

SN - 0090-4295

ER -